We are an immuno-oncology company specializing in cancer therapeutics.
We have a comprehensive intellectual property portfolio for imaging and treatment of solid tumors to improve patient outcomes.
Learn More GlyTherix
Therapeutic & Imaging Applications Miltuximab® Our patented antibodies target human glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, glioblastoma, esophageal and other solid tumors.
We have completed a First-in-Human (FIH) trial using our antibody, called Miltuximab®.
Learn More
Our patented antibodies target GPC-1, a protein over expressed in prostate, pancreatic, bladder, esophageal and other solid tumors
We have completed a first in human trial using our antibody, called Miltuximab
News More Find out about the vital work we do
developing solid tumor therapeutics.

Miltuximab® for Therapeutic & Imaging Applications.

Our patented antibodies target Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, glioblastoma, esophageal and ovarian cancers.
We are examining multiple mechanisms of action including:

– Radioimmunotherapy
– Bispecific antibodies
– Immune cell engagement and activation

We have now completed a First-in-Human trial in Australia using Miltuximab®, our anti-GPC-1 monoclonal antibody (ANZCTR registry).

The trial dosed 12 patients and no drug-related adverse events were observed.

Glytuzumab® refers to the humanized version of Miltuximab® and also targets human GPC-1. The Glytuzumab® program is currently undergoing Lead Optimization and Lead Selection. Several humanized leads have been generated with similar binding affinities to that of the parent molecule Miltuximab®. The final Glytuzumab® lead selected will be taken forward from cell line development through to large scale GMP production for future clinical trials.

Achievements

N

2019

N

Preclinical work now completed for upcoming Phase I clinical trial in GPC-1 expressing solid tumours. This will use Miltuximab® labelled with either 89Zirconium for imaging or 177Lutetium for therapy

N

First-in-Human clinical trial of Miltuximab® labelled with 67Gallium for imaging met primary endpoint of safety in all 12 patients

N

Antibody composition of matter patents granted EU and US

N

2018

N

Completion of accrual for clinical study of Miltuximab® in prostate, bladder and pancreatic cancers

N

2017

N

The second stage of pioneering MILGa clinical trial of Miltuximab®

N

2016

N

Commenced First-In-Human trial of Miltuximab® 

2015 Eureka Prize

Excellence in Interdisciplinary Scientific Research

Major Australian prize for innovation awarded to our CEO, Brad Walsh, and university collaborators.

Find Out More Information

  • About our groundbreaking first-in-human trial of our novel cancer target >More
  • About how your company and Glytherix could partner to deliver better cancer therapeutics >More 

13 + 8 =

Privacy Policy